fashion -WSS

fashion

author：comprehensive 2025-10-02 23:31:40 - browse：7

FogPharma CEO Mathai Mammen Venrock

SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： New weight loss drugs vying to be the next Wegovy or Mounjaro

WSS

How housing is health care on Long Island

Popular nasal decongestant doesn't actually relieve congestion

Patients, digital health players weigh in on FTC's data privacy plan

White House touts steps to stem shortages of cancer treatments

WATCH: Why do bright lights make us see spots?

Dozens dead from Maui wildfires: What we know about the victims

focus

fashion

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA approves updated Covid vaccines

The high cost of giving birth even with insurance

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Illumina slashes 2023 revenue projections yet again

Virginia high school admissions case could be legal follow

WATCH: Why do bright lights make us see spots?

Cancer drug shortages should be causing more outrage

Walmart eyes Medicare Advantage provider ChenMed

knowledge

FDA approves updated Covid vaccines

Private equity could exacerbate cardiology's overuse problem, experts fear

Novo Nordisk touts Wegovy study, but still struggling with supply

FDA proposes changes to key medical devices approval pathway

Timeline: How the deadly wildfires took over Maui day by day

Diverse clinical trials: Why aren’t we there yet?

explore

focus

hotspot

entertainment